Award Data

DESCRIPTION (provided by applicant): Adolescents in mental health treatment are at greater risk for HIV and other STIs than their peers due to an earlier age of onset of sex, less protected sex, more sexual partners, and more frequent substance use. This greater risk is due to multiple factors including cognitive misperceptions, affect dysregulation, and less self efficacy. The numerous adolescent ...

DESCRIPTION (provided by applicant): HIV/AIDS remains a major health problem and there is a need for effective and durable HIV vaccines. Establishing potent and durable antibodies (Ab) that have neutralizing and non-neutralizing mechanisms can contribute to the prevention of mucosal HIV infection. Findings from the recent RV144 trial have highlighted a significant role for protective non-neutraliz ...

DESCRIPTION (provided by applicant): The objective of this proposal is to complete development of a long-term, universal Apical Access System (AAS) to improve clinical outcomes and expand the role of left ventricular assist device (LVAD) therapy. The treatment of end stage heart failure (HF) is the greatest challenge, both clinically and economically to the U.S. health care system today. With gt80 ...

DESCRIPTION (provided by applicant): The manufacturing of recombinant coagulation factor VIII is a complex, labor and capital intensive endeavor. Of the recombinant proteins currently marketed, coagulation factor VIII is manufactured with the lowest efficiency and is by far the most expensive on a per unit mass basis with a pharmacy price of 10,000,000 per gram. The goal of the current applicatio ...

DESCRIPTION: Incremental improvements in label free screening technologies over the past decade have not produced the capability necessary to support the changing needs of drug discovery programs. Persistent artifacts related to non-specific binding, promiscuous binding, precipitation, complex binding, tubing retention, aggregation, and sub-optimally designed platforms continue to hinder progress ...

DESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induced progressive multifocal leukoencephalopathy (PML). PMLis a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid-1980s ...

Access to a library of structurally defined N-glycans is an urgent scientific need for glyco-arrays for rapid analysis of carbohydrate binding proteins (CBPs), development of diagnostics and therapeutics for many diseases. However, only a small number ofN-glycans are currently commercially available, which hampered researches in Glycobiology. This application will chemo-enzymatically prepare a ...

DESCRIPTION (provided by applicant): There is a great need for new therapies for Crohn's disease (CD), which is a chronic, relapsing and tissue destructive inflammatory bowel disease (IBD). Estimates indicate that there are gt 1 million annual cases of IBDin the United States, 50% of which involve CD. Our primary objective is to develop a biologic that can be used to better treat and reduce t ...

DESCRIPTION (provided by applicant): LumaMed LLC proposes developing LumaScan , an innovative, cost effective and easy to use device for visualizing tumor margins during Breast Conservation Surgery (BCS), a method that is used in about 60-70% percent of breast cancer surgeries. Currently, breast tumors are approximately located using methods such as MRI or CT in a preoperative procedure. During s ...

DESCRIPTION (provided by applicant): Obesity is considered the number one health problem in the US and Europe, affecting 10% to 30% of adult populations. Obese individuals are more likely to acquire a variety of secondary diseases including diabetes, heartproblems, immune deficiencies, some types of cancer, and osteoarthritis and they die younger than non-obese individuals. Obesity results from th ...